Financial Performance Highlights
Consolidated Results (H1 FY27)
- Total Income: ₹615.54 million (₹6,155.35 lakhs)
- Profit After Tax (PAT): ₹32.75 million (₹327.46 lakhs), compared to loss of ₹2.13 million (₹-21.30 lakhs) in H1 FY26
Consolidated Results (Q2 FY27)
- Total Income: ₹298.52 million (₹2,985.24 lakhs)
- Revenue from Operations: ₹294.17 million (₹2,941.68 lakhs)
- Net Profit: ₹22.12 million (₹221.20 lakhs), representing 108.17% quarter-on-quarter growth from ₹10.63 million in Q1 FY27
- Earnings Per Share (Basic & Diluted): ₹0.15
Standalone Results (H1 FY27)
- Total Income: ₹280.52 million (₹2,805.22 lakhs)
- Net Profit: ₹31.89 million (₹318.92 lakhs), compared to loss of ₹7.83 million (₹-78.30 lakhs) in H1 FY26
Standalone Results (Q2 FY27)
- Total Income: ₹147.55 million (₹1,475.54 lakhs), growing 10.97% quarter-on-quarter from ₹132.97 million in Q1 FY27
- Revenue from Operations: ₹143.20 million (₹1,431.98 lakhs)
- Net Profit: ₹22.21 million (₹222.09 lakhs), representing 129.36% quarter-on-quarter growth from ₹9.68 million in Q1 FY27
- Earnings Per Share (Basic & Diluted): ₹0.15
Strategic Business Initiatives
The company announced several strategic initiatives to advance its vision across digital healthcare, AI and longevity sciences:
1. TAKE.Health: Launch of an intelligent digital health companion designed to integrate lifestyle and medical data into personalized, actionable health insights
2. Innovation Fund: Establishment of a ₹50 million (₹5 crore) Innovation Fund with initial corpus commitment to identify, invest in and support high-potential startups operating across Artificial Intelligence, deep technology and digital health
3. Longevity Market Entry: Strategic entry into India's longevity and anti-ageing market with plans to develop science-backed nutraceuticals, biohacking-focused products and technology-enabled preventive healthcare solutions
Board Meeting Details
- Meeting Date: November 13, 2026
- Commencement Time: 05:00 PM IST
- Conclusion Time: 06:15 PM IST
- Business Approved: Unaudited Standalone and Consolidated Financial Results for quarter and half year ended September 30, 2026, along with Limited Review Reports and Press Release
Financial Statement Details
Standalone Financial Position (as of September 30, 2026)
- Total Assets: ₹3,310.47 lakhs (Previous year: ₹3,004.99 lakhs)
- Equity Share Capital: ₹1,479.34 lakhs (unchanged)
- Other Equity: ₹1,688.35 lakhs (Previous: ₹1,369.43 lakhs)
- Cash and Cash Equivalents: ₹53.06 lakhs (Previous: ₹26.42 lakhs)
Consolidated Financial Position (as of September 30, 2026)
- Total Assets: ₹4,018.13 lakhs (Previous year: ₹3,624.11 lakhs)
- Equity Share Capital: ₹1,479.34 lakhs (unchanged)
- Other Equity: ₹1,948.25 lakhs (Previous: ₹1,620.79 lakhs)
- Cash and Cash Equivalents: ₹94.76 lakhs (Previous: ₹25.96 lakhs)
Consolidated Entities Included
1. TAKE Ventures Private Limited
2. Navitas LLP
Auditor Review
The Limited Review of the Unaudited Standalone and Consolidated Financial Results was conducted by A. Raghavendra Rao & Associates, Chartered Accountants (Firm Reg No: 003324S). The review was performed in accordance with Standard on Review Engagements (SRE) 2410 issued by ICAI. The auditors concluded that nothing came to their attention causing them to believe that the financial results were not prepared in all material respects in accordance with applicable accounting standards.
Management Commentary
Mr. Sunil Patra, Managing Director, stated: "The first half of FY2026-27 represents an important period for TAKE Limited as we have made progress in strengthening our financial performance while advancing our strategic priorities. Our return to profitability across consolidated and standalone operations is an encouraging development. We are particularly focused on the convergence of healthcare, science and technology."
Notes to Financial Results
1. The Company's business activity falls within a single primary business segment
2. Provisions for taxes, if any, shall be made at the end of the year
3. Previous period figures have been regrouped and reclassified wherever necessary